Effects of intravenous magnesium sulphate in acute myocardial infarction.

This column reviews the results of second Leicester Intravenous Magnesium Sulphate Intervention Trial (LIMIT-2), a clinical study investigating the effects of intravenous magnesium sulphate on 28-day mortality and morbidity in suspected AMI patients. Many LIMIT-2 subjects also received thrombolytic and anti-platelet therapy, differentiating findings of this study from earlier results. Implications for practice, education, and future research are discussed.